Swedbank AB Has $310.31 Million Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

Swedbank AB lifted its holdings in Royalty Pharma plc (NASDAQ:RPRX) by 10.3% during the 4th quarter, Holdings Channel reports. The fund owned 12,164,170 shares of the biopharmaceutical company’s stock after acquiring an additional 1,136,800 shares during the quarter. Swedbank AB’s holdings in Royalty Pharma were worth $310,308,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Dimensional Fund Advisors LP lifted its stake in shares of Royalty Pharma by 21.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 787,257 shares of the biopharmaceutical company’s stock worth $20,765,000 after buying an additional 139,761 shares during the last quarter. Sei Investments Co. increased its holdings in shares of Royalty Pharma by 81.7% during the second quarter. Sei Investments Co. now owns 69,071 shares of the biopharmaceutical company’s stock valued at $1,821,000 after acquiring an additional 31,055 shares in the last quarter. Toronto Dominion Bank lifted its position in Royalty Pharma by 5.2% in the 2nd quarter. Toronto Dominion Bank now owns 43,714 shares of the biopharmaceutical company’s stock valued at $1,153,000 after acquiring an additional 2,172 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of Royalty Pharma by 69.0% in the second quarter. AQR Capital Management LLC now owns 785,567 shares of the biopharmaceutical company’s stock valued at $20,715,000 after purchasing an additional 320,606 shares during the last quarter. Finally, MBB Public Markets I LLC bought a new stake in Royalty Pharma in the second quarter worth about $715,000. Institutional investors own 54.35% of the company’s stock.

Analyst Upgrades and Downgrades

RPRX has been the topic of several recent analyst reports. Citigroup lowered their target price on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. TD Cowen upgraded Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. Finally, StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $41.67.

Royalty Pharma Trading Up 0.7 %

Shares of RPRX traded up $0.21 during midday trading on Wednesday, hitting $32.15. 139,956 shares of the stock were exchanged, compared to its average volume of 4,048,033. Royalty Pharma plc has a 52-week low of $24.05 and a 52-week high of $32.19. The stock has a fifty day simple moving average of $27.01 and a 200 day simple moving average of $27.44. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.54 and a current ratio of 1.54. The firm has a market cap of $18.94 billion, a P/E ratio of 16.65 and a beta of 0.47.

Royalty Pharma Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 21st will be given a $0.22 dividend. The ex-dividend date is Friday, February 21st. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a dividend yield of 2.74%. Royalty Pharma’s payout ratio is currently 43.52%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.